Literature DB >> 20098977

[Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax].

M Halank1, C P Strassburg, M M Hoeper.   

Abstract

Hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax are typical pulmonary complications in patients with liver cirrhosis. Whereas hepatopulmonary syndrome and portopulmonary hypertension represent pulmonary vascular diseases, the development of hepatic hydrothorax is associated with the presence of ascites and phrenic lesions. For severe hepatopulmonary syndrome and refractory hepatic hydrothorax, liver transplantation is the treatment of choice. In severe portopulmonary hypertension specific medical treatment is indicated. In selected patients, beside intravenous prostanoids, oral endothelin receptor antagonists and phosphodiesterase type-5 inhibitors are possible treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 20098977     DOI: 10.1007/s00108-009-2503-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Usefulness and complications of thoracentesis in cirrhotic patients.

Authors:  X Xiol; J Castellote; R Cortes-Beut; M Delgado; J Guardiola; E Sesé
Journal:  Am J Med       Date:  2001-07       Impact factor: 4.965

2.  Clinical practice. Pleural effusion.

Authors:  Richard W Light
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 3.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

Review 4.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

Review 5.  [Portopulmonary hypertension].

Authors:  M Halank; S Miehlke; M Kolditz; G Hoeffken
Journal:  Z Gastroenterol       Date:  2005-07       Impact factor: 2.000

6.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 7.  Screen for portopulmonary hypertension, especially in liver transplant candidates.

Authors:  Karen L Swanson; Michael J Krowka
Journal:  Cleve Clin J Med       Date:  2008-02       Impact factor: 2.321

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax.

Authors:  Patrick G Northup; R Christopher Harmon; Timothy L Pruett; Worthington G Schenk; Thomas M Daniel; Carl L Berg
Journal:  Ann Thorac Surg       Date:  2009-01       Impact factor: 4.330

10.  Experience with inhaled iloprost and bosentan in portopulmonary hypertension.

Authors:  M M Hoeper; H J Seyfarth; G Hoeffken; H Wirtz; E Spiekerkoetter; M W Pletz; T Welte; M Halank
Journal:  Eur Respir J       Date:  2007-07-25       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.